For verified researchers & institutions
This policy reflects advice from professional bodies, such as the American College of Occupational and Environmental Medicine (ACOEM), which notes that the present availability of coverage for obesity care is piecemeal and calls for guidance on how to operationalize evidence-based behavioral, nutritional, pharmacological, and surgical obesity treatment modalities as health benefits. The ACOEM further notes that obesity represents an ongoing cost to employers and society at large in the form of current and future health care expenses, absenteeism, presenteeism, and workers compensation costs related to injuries and illnesses. OPMs 2025 Call Letter, issued January 15, 2025, identified this context of rising utilization and cost amidst inconsistent application of comprehensive, evidence-based care
Randomized, double-blind, placebo-controlled trial of the once-daily glp-1 receptor agonist lixisenatide in asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (Getgoal-L-Asia)
GLP-1s were recently declared proven longevity medicine from the keynote stage at a major pharmaceutical industry conference in Copenhagen, which was chronicled in the journal Nature last month. Dr
